Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00987805
Other study ID # B090029
Secondary ID ISRCTN51910678
Status Completed
Phase Phase 4
First received September 30, 2009
Last updated June 20, 2012
Start date September 2009
Est. completion date January 2011

Study information

Verified date June 2012
Source Korea Health Industry Development Institute
Contact n/a
Is FDA regulated No
Health authority Korea: Ministry for Health and Welfare
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess efficacy based on Gastrointestinal Symptom score and safety based on the rate of adverse event or laboratory findings of Banhasasim-tang administrated three times a day orally on functional dyspepsia.


Description:

Banhasasim-tang

1. Main 3 gram herb powder (including Rhizoma Pinelliae, Radix Scutellariae, Zingiberis Rhizoma, Panax ginseng, Glycyrrhiza uralensis Fisch, Zizyphi Fructus and Coptidis Rhizoma) of old oriental prescriptions for dyspepsia.

2. Usually having used for dyspepsia in asia

3. Need for correct clinical information by RCT


Recruitment information / eligibility

Status Completed
Enrollment 84
Est. completion date January 2011
Est. primary completion date January 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Typical functional dyspepsia according to ROME III criteria.

- One or more of:

- Bothersome post-prandial fullness

- Early satiation

- Epigastric pain

- Epigastric burning

- No evidence of structural disease (including at upper endoscopy) that is likely to explain the symptoms

2. The presence of 'moderate' as the degree of severity for at least three Gastrointestinal Symptom (GIS) score symptoms

3. Before participation of trial, epigastric pain or discomfort has persisted in a permanent or recurrent form for a minimum period of 12 weeks

4. Written and informed consent

Exclusion Criteria:

1. History of peptic ulcer or gastroesophageal reflux disease(GERD)

2. Current prominent symptoms of irritable bowel syndrome or GERD

3. Presence of the following alarm symptoms:

- Severe weight loss

- Black or tar stool

- Dysphagia

4. Presence of the following diseases (like cholangitis, pancreatitis, etc.) or uncontrolled severe organ disorders

5. Women in pregnancy and lactation

6. History of gastrointestinal surgery or taking any drugs that may significantly alter digestive system

7. Participation of other clinical trials within the last 3 months

8. Severe mental problems or drug abuse

9. Judged by expert that they are appropriate to participate in this study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Banhasasim-tang
Form : granules Contents : It consists of seven Herbs. It contains Rhizoma Pinelliae, Radix Scutellariae, Zingiberis Rhizoma, Panax ginseng, Glycyrrhiza uralensis Fisch, Zizyphi Fructus and Coptidis Rhizoma Dosage and frequency : 9g per day (three times a day) Route of administration : Oral Administration duration : 42 days in the study
Corn-starch granules
This placebo has the same form, color, and flavor as experimental intervention.The dosage, frequency and duration is also same as experimental intervention.

Locations

Country Name City State
Korea, Republic of East-West Neo Medical Center Seoul
Korea, Republic of Kyung Hee University Medical Center Oriental Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Korea Health Industry Development Institute

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Gastrointestinal Symptom (GIS) score (epigastric pain/upper abdominal pain, abdominal cramps, fullness, early satiety, loss of appetite, sickness, nausea, vomiting, retrosternal discomfort, and acidic regurgitation/heartburn) Baseline, 2 weeks, 4 weeks, 6 weeks after administration, 4 and 8 weeks after treatment finish No
Secondary Visual Analogue Scale (VAS) for overall discomfort due to dyspepsia Baseline, 2weeks, 4weeks, 6weeks after administration, 4 and 8 weeks after treatment finish No
Secondary Functional Dyspepsia-related Quality of Life (FD-QoL) Baseline, 2 weeks, 4 weeks, and 6 weeks after administration, 4 and 8 weeks after treatment finish No
Secondary Electrogastrography (EGG) Baseline, 6 weeks after administration No
See also
  Status Clinical Trial Phase
Completed NCT04656730 - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Phase 4
Completed NCT04464369 - Functional Dyspepsia: Validation of the Leuven Postprandial Distress Scale (LPDS) in a Placebo-controlled Trial Phase 4
Completed NCT01671670 - Acupuncture for Patients With Function Dyspepsia Phase 2/Phase 3
Completed NCT00693407 - Study of Endogenous Inhibitory Modulation During Gastric and Somatic Stimulation N/A
Completed NCT00761358 - To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia Phase 3
Recruiting NCT01240096 - Mirtazapine Versus Placebo in Functional Dyspepsia Phase 4
Recruiting NCT04540549 - Effects of Exercise on Functional Dyspepsia Based on Rome IV N/A
Recruiting NCT03652571 - Nortriptyline for the Treatment of Functional Dyspepsia Phase 3
Recruiting NCT06068114 - Gastric Pathophysiology in Diabetes
Recruiting NCT03825692 - International Clinical Study of Zhizhu Kuanzhong Capsule Phase 4
Not yet recruiting NCT04548011 - Acupuncture of Different Treatment Frequency on Improving Quality of Life in Patients With Functional Dyspepsia N/A
Terminated NCT02567578 - A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia Phase 2
Completed NCT03007433 - Assessment of GI Function to a Large Test Meal by Non-invasive Imaging N/A
Active, not recruiting NCT00990405 - Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia Phase 4
Completed NCT00404534 - Helicobacter Eradication Relief of Dyspeptic Symptoms Phase 3
Completed NCT03043625 - Visceral Manipulation Treatment to Patients With Non-specific Neck Pain With Functional Dyspepsia N/A
Completed NCT03225248 - Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia Phase 3
Recruiting NCT05587127 - Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia N/A
Recruiting NCT01021475 - Does Visceral Manipulation Works in Treating Functional Dyspepsia? Phase 1
Completed NCT00599677 - Randomized Controlled Trial of Acupuncture for Functional Dyspepsia N/A